CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
CANDEL THERAPEUTICS, INC. (CADL) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $48.33 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $48.33M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $10.55M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $13.70M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $11.39M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $48.33M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $10.55M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $13.70M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $11.39M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $11.27M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $13.85M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $27.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $20.30M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $17.39M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $378.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $199.00K 10-K · filed 2025-03-13 |
| 2023-06-30 | $10.00M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $7.00M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $881.00K 10-K · filed 2023-03-30 |
| 2021-12-31 | $26.39M 10-K · filed 2022-03-29 |
| 2020-12-31 | $13.82M 10-K · filed 2022-03-29 |
| 2019-12-31 | $120.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |